[{"id":"bacf0a9a-d80e-41ef-a188-b717b8ce2cef","acronym":"","url":"https://clinicaltrials.gov/study/NCT03343678","created_at":"2021-01-18T16:30:48.751Z","updated_at":"2024-07-02T16:37:15.018Z","phase":"Phase 1","brief_title":"This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclax","source_id_and_acronym":"NCT03343678","lead_sponsor":"Boehringer Ingelheim","biomarkers":" TP53","pipe":" | ","alterations":" TP53 mutation","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • BI 836826"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/17/2018","start_date":" 01/17/2018","primary_txt":" Primary completion: 05/25/2018","primary_completion_date":" 05/25/2018","study_txt":" Completion: 11/25/2020","study_completion_date":" 11/25/2020","last_update_posted":"2018-01-09"}]